UNSPSC 51271633: Prilocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C13H20N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MJW015BAPH, chemically known as propanamide, n-(2-methylphenyl)-2-(propylamino)-, monohydrochloride but more generally known as prilocaine hydrochloride, which bears US NIH Compound Identifier 92163. European Medicines Agency schedules Prilocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04038MIG.

Most nations, for tariff and trade purposes, schedule prilocaine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, PRILOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Prilocaine hydrochloride bears US NLM identifiers UMLS ID C0591261 and NCI Concept Code C48012. SMILES: CCCNC(C)C(=O)NC1CCCCC1C.CL.

UNSPSC 51271633 Prilocaine hydrochloride, a Commodity code, encompasses anesthetic pharmaceutical products that state and local health systems and cooperative purchasing alliances procure for use across clinical and procedural settings. State and local governments source this code primarily through multistate cooperative purchasing agreements rather than direct individual-jurisdiction solicitations, leveraging volume commitments to negotiate favorable pricing from pharmaceutical manufacturers and managing distribution through established wholesaler networks.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP posted January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including anesthetics such as prilocaine hydrochloride, to supply participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencala, Cardinal Health 110 and 112, or Morris & Dickson Co., LLC) with chargeback systems in place, certify cGMP and DSCSA compliance, and offer pricing in formats including flat price, net price (NF30, NF60, NF90), or WAC-minus structures. Evaluation weighting favors price competitiveness at 75 percent, with secondary criteria addressing administrative fee compliance (5 percent), EDI capability (5 percent), fixed pricing terms (10 percent), and 3 percent administrative fee acceptance (5 percent). Products must be available by May 15, 2026, with contract effectiveness set for July 1, 2026 and a two-year initial term for new vendors. The RFP specifies no set-aside designations or disadvantaged-enterprise restrictions.